Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway

Journal of Cellular Physiology

Volumn 220, Issue 1, 2009, Pages 257-266

  Tyagi, Neetu ^a   Gillespie, William ^a   Vacek, Jonathan C ^a   Sen, Utpal ^a   Tyagi, Suresh C ^a   Lominadze, David ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; COLLAGEN TYPE 4; ELASTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; HOMOCYSTEINE; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MUSCIMOL; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; THIOREDOXIN; TISSUE INHIBITOR OF METALLOPROTEINASE 4; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; MMP9 PROTEIN, MOUSE; NOS2 PROTEIN, MOUSE; NOS3 PROTEIN, MOUSE; NOX4 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE-4;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION;

ANIMALS; CELL LINE; COLLAGEN TYPE IV; ELASTIN; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GABA AGONISTS; HOMOCYSTEINE; MATRIX METALLOPROTEINASE 9; MICE; MUSCIMOL; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; RECEPTORS, GABA-A; SIGNAL TRANSDUCTION; THIOREDOXINS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 65549159487     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21757     Document Type: Article

References (60)

1. Anuradha H, Srikumar BN, Shankaranarayana Rao BS, Lakshmana M. 2008. Euphorbia hirta reverses chronic stress-induced anxiety and mediates its action through the GABA(A) receptor benzodiazepine receptor-Cl(-) channel complex. J Neural Transm 115:35-42.
2. Baum T, Becker F. 1982. Hypotensive and postural effects of the gamma-aminobutyric acid agonist muscimol and of clonidine. J Cardiovasc Pharmacol 4:165-169.
3. Bogoyevitch MA, Ng DCH, Court N, Draper KA, Dhillon A, Abas L. 2000. Intact mitochondrial electron transport function is essential for signalling by hydrogen peroxide in cardiac myocytes. J Mol Cell Cardiol 32:1469-1480.
4. Brew K, Dinakarpandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim Biophys Acta 1477:267-283.
5. Bulleit RF, Hsieh T. 2000. MEK inhibitors block BDNF-dependent and -independent expression of GABA(A) receptor subunit mRNAs in cultured mouse cerebellar granule neurons. Brain Res Dev Brain Res 119:1-10.
6. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE. 2008. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198:320-331.
7. Chae HZ, Chung SJ, Rhee SG. 1994. Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem 269:27670-27678.
8. Dworakowski R, Anilkumar N, Zhang M, Shah AM. 2006. Redox signalling involving NADPH oxidase-derived reactive oxygen species. Biochem Soc Trans 34:960-964.
9. Edirimanne VER, Woo CWH, Siow YL, Pierce GN, Xie JYOK. 2007. Homocysteine stimulates NADPH oxidase-mediated superoxide production leading to endothelial dysfunction in rats. Can J Physiol Pharmacol 85:1236-1247.
10. Frolund B, Ebert B, Kristiansen U, Liljefors T, Krogsgaard-Larsen P. 2002. GABA-A receptor ligands and their therapeutic potentials. Curr Top Med Chem 2:817.
11. Fruscella P, Sottocorno M, Di BM, Diomede L, Piccardi N, Cagnotto A, Grossi G, Romano M, Mennini T, Roma G. 2001. 1, 5-Benzodiazepine tricyclic derivatives exerting anti-inflammatory effects in mice by inhibiting interleukin-6 and prostaglandin E(2)production. Pharmacol Res 43:445-452.
12. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJR, Knowles RG. 1997. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 272:4959-4963.
13. Griffiths R, Williams DC, O'Neill C, Dewhurst IC, Ekuwem CE, Sinclair CD. 1983. Synergistic inhibition of [3H]muscimol binding to calf-brain synaptic membranes in the presence of L-homocysteine and pyridoxal 5′-phosphate. A possible mechanism for homocysteine-induced seizures. Eur J Biochem 137:467-478.
14. Haorah J, Ramirez SH, Schall K, Smith D, Pandya R, Persidsky Y. 2007. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J Neurochem 101:566-576.
15. Hashimoto T, Wen G, Lawton MT, Boudreau NJ, Bollen AW, Yang GY, Barbaro NM, Higashida RT, Dowd CF, Halbach VV, Young WL. 2003. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke 34:925-931.
16. Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, Shea TB. 2001. Homocysteine potentiates β-amyloid neurotoxicity: Role of oxidative stress. J Neurochem 78:249-253.
17. Hunt MJ, Aru GM, Hayden MR, Moore CK, Hoit BD, Tyagi SC. 2002. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol 283:L239-L245.
18. Jacobsen DW. 2000. Hyperhomocysteinemia and oxidative stress: Time for a reality check? Arterioscler Thromb Vasc Biol 20:1182-1184.
19. Ji C, Kaplowitz N. 2004. Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury. World J Gastroenterol 10:1699-1708.
20. Jourquin J, Tremblay E, Decanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatisky M, Rivera S. 2003. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci 18:1507.
21. Kang KA, Zhang R, Piao MJ, Ko DO, Wang ZH, Lee K, Kim BJ, Shin T, Park JW, Lee NH, Yoo BS, Hyun JW. 2008. Inhibitory effects of triphlorethol-A on MMP-1 induced by oxidative stress in human keratinocytes via ERK and AP-1 inhibition. J Toxicol Environ Health Part A 71:992-9999.
22. Kishi T, Hirooka Y, Sakai K, Shigematsu H, Shimokawa H, Takeshita A. 2001. Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release. Hypertension 38:896-901.
23. Ku BM, Lee YK, Jeong JY, Mun J, Han JY, Roh GS, Kim HJ, Cho GJ, Choi WS, Yi GS, Kang SS. 2007. Ethanol-induced oxidative stress is mediated by p38 MAPK pathway in mouse hippocampal cells. Neurosci Lett 419:64-67.
24. Laude K, Favre J, Thuillez C, Richard V. 2003. NO produced by endothelial NO synthase is a mediator of delayed preconditioning-induced endothelial protection. Am J Physiol Heart Circ Physiol 284:H2053-H2060.
25. Lazzarini R, Malucelli BE, Palermo-Neto J. 2001. Reduction of acute inflammation in rats by diazepam: Role of peripheral benzodiazepine receptors and corticosterone. Immunopharmacol Immunotoxicol 23:253-265.
26. Lee WS, Limmroth V, Ayata C, Cutrer FM, Waeber C, Yu X, Moskowitz MA. 1995. Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 116:1661-1667.
27. Limmroth V, Lee WS, Moskowitz MA. 1996. GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol 117:99-104.
28. Liu QY, Chang YH, Schaffner AE, Smith SV, Barker JL. 2002. Allopregnanolone activates GABAA receptor/Cl- channels in a multiphasic manner in embryonic rat hippocampal neurons. J Neurophysiol 88:1147-1158.
29. Lominadze D, Roberts A, Tyagi N, Tyagi S. 2006. Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Circ Physiol 290:H1206-H1213.
30. Lu Y, Wahl LM. 2005. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-{kappa}B activity in lipopolysaccharide-activated human primary monocytes. J Immunol 175:5423-5429.
31. Mannello F, Gazzanelli G. 2001. Tissue inhibitors of metalloproteinases and programmed cell death: Conundrums, controversies, and potential implications. Apoptosis 6:479-482.
32. Montesano R, Pepper M, Mohle-Steinlein U, Risau W, Wagner E, Orci L. 1990. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62:435-445.
33. Moshal KS, Sen U, Tyagi N, Henderson B, Steed M, Ovechkin AV, Tyagi SC. 2006a. Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway. Am J Physiol Cell Physiol 290:C883-C891.
34. Moshal K, Singh M, Sen U, Rosenberger D, Henderson B, Tyagi N, Zhang H, Tyagi SC. 2006b. Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol 291:H2825-H2835.
35. Mujumdar V, Tyagi S. 1999. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens 17:261-270.
36. Mujumdar VS, Smiley LM, Tyagi SC. 2001. Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength. Int J Cardiol 79:277-286.
37. Nakamura H, Matsuda M, Furuke K, Kitaoka Y, Iwata S, Toda K, Inamoto T, Yamaoka Y, Ozawa K, Yodoi J. 1994. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett 42:75-80.
38. Obeid R, Herrmann W. 2006. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 580:2994-3005.
39. Okuda M, Inoue N, Azumi H, Seno T, Sumi Y, Hirata KI, Kawashima S, Hayashi Y, Itoh H, Yodoi J, Yokoyama M. 2001. Expression of glutaredoxin in human coronary arteries: Its potential role in antioxidant protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21:1483-1487.
40. Perry TL, Hansen S, MacDougall L, Warrington PD. 1967. Sulfur-containing amino acids in the plasma and urine of homocystinurics. Clinica Chimica Acta 15:409-420.
41. Reis G, Pacheco D, Francischi J, Castro M, Perez A, Duarte I. 2007. Involvement of GABAA receptor-associated chloride channels in the peripheral antinociceptive effect induced by GABAA receptor agonist muscimol. Eur J Pharmacol 564:112-115.
42. Robert K, Pages C, Ledru A, Delabar J, Caboche J, Janel N. 2005. Regulation of extracellular signal-regulated kinase by homocysteine in hippocampus. Neuroscience 133:925-935.
43. Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernandez-Cadenas I, Penalba A, Molina CA, Montaner J. 2005. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36:1415-1420.
44. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M, Molina CA, Lo EH, Montaner J. 2006. Increased brain expression ofmatrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37:1399-1406.
45. Rosenberg GA. 2009. Matrix metalloproteinases in neuroinflammation. Glia 39:279-291.
46. Sachdev PS, Valenzuela M, Wang XL, Looi JCL, Brodaty H. 2002. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 58:1539-1541.
47. Santiard-Baron D, Aupetit J, Janel N. 2005. Plasma homocysteine levels are not increased in murine models of Alzheimer's disease. Neurosci Res 53:447-449.
48. Shastry S, Moning L, Tyagi N, Steed M, Tyagi S. 2005. GABA receptors and Nitric oxide ameliorate constrictive collagen remodeling on hyperhomocysteinemia. J Cell Physiol 205:422-427.
49. Shastry S, Tyagi N, Moshal K, Lominadze D, Hayden M, Tyagi S. 2006. GABA receptors ameliorate Hcy-mediated integrin shedding and constrictive collagen remodeling in microvascular endothelial cells. Cell Biochem Biophys 45:157-165.
50. Sood HS, Cox MJ, Tyagi SC. 2002. Generation of nitrotyrosine precedes activation of metalloproteinase in myocardium of hyperhomocysteinemic rats. Antioxidants Redox Signal 4:799-804.
51. Sternlicht MD, Werb Z. 2001. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463.
52. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. 2005. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 289:H2649-H2656.
53. Tyagi N, Ovechkin A, Lominadze D, Moshal K, Tyagi S. 2006. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem 98:1150-1162.
54. Tyagi N, Moshal KS, Tyagi SC, Lominadze D. 2007. γ-aminbutyric acid A receptor mitigates homocysteine-induced endothelial cell permeability. Endothelium 14:315-323.
55. Unger T, Becker H, Dietz R, Ganten D, Lang RE, Rettig R, Schomig A, Schwab NA. 1984. Antihypertensive effect of the GABA receptor agonist muscimol in spontaneously hypertensive rats. Role of the sympathoadrenal axis. Circ Res 54:30-37.
56. Valentin F, Bueb JL, Kieffer P, Tschirhart E, Atkinson J. 2005. Oxidative stress activates MMP-2 in cultured human coronary smooth muscle cells. Fundam Clin Pharmacol 19:661-667.
57. Wald DS, Law M, Morris JK. 2002. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 325:1202-1206.
58. Wang YJ, Ho YS, Pan MH, Lin JK. 1998. Mechanisms of cell death induced by nitric oxide and peroxynitrite in Calu-1 cells. Environ Toxicol Pharmacol 6:35-44.
59. Yamawaki H, Haendeler J, Berk BC. 2003. Thioredoxin: A key regulator of cardiovascular homeostasis. Circ Res 93:1029-1033.
60. Zhang JW, Deb S, Gottschall PE. 1998. Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration. Eur J Neurosci 10:3358-3368.